1. Home
  2. OIS vs IMMP Comparison

OIS vs IMMP Comparison

Compare OIS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oil States International Inc.

OIS

Oil States International Inc.

HOLD

Current Price

$7.10

Market Cap

406.3M

Sector

Industrials

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.56

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OIS
IMMP
Founded
1995
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.3M
264.9M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
OIS
IMMP
Price
$7.10
$2.56
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
645.5K
1.7M
Earning Date
10-31-2025
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.38
N/A
Revenue
$655,119,000.00
$3,306,742.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.51
N/A
P/E Ratio
$18.55
N/A
Revenue Growth
N/A
31.28
52 Week Low
$3.08
$1.32
52 Week High
$7.19
$3.53

Technical Indicators

Market Signals
Indicator
OIS
IMMP
Relative Strength Index (RSI) 67.32 72.34
Support Level $6.63 $1.67
Resistance Level $7.19 $2.68
Average True Range (ATR) 0.24 0.25
MACD 0.08 0.09
Stochastic Oscillator 93.50 48.12

Price Performance

Historical Comparison
OIS
IMMP

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: